PD-L1 expression guides immunotherapy decisions in non small cell lung cancer (NSCLC), yet sample type can impact assessment accuracy. This study aimed to compare PD-L1 expression between small (biopsies, cell blocks) and large (resection) NSCLC samples, assess interobserver variability, and examine whether PD-L1 scoring trends remained stable over a multi-year period.
Methods
A retrospective analysis was conducted on 494 NSCLC patients tested for PD-L1 (Ventana SP263) between 2018 and 2022. Sample type, tumor subtype, PD-L1 tumor proportion score (TPS), and reporting pathologist were recorded. Interobserver variability was analyzed based on routine diagnostic reports from different pathologists evaluating non-overlapping patient cohorts. Additionally, a subset of 43 patients had matched cell block and resection specimens collected from the same tumor, allowing direct comparison between preparations.
Results
Among the 494 NSCLC specimens, 152 were large and 342 were small samples. TPS results showed 112 samples (22%) with TPS ≥ 50%, 163 (34%) with TPS 1%–49%, and 219 (44%) with TPS < 1%. No significant differences in TPS categories were observed between cell blocks and tissue samples (p = 0.176) or between small and large samples (p = 0.326). TPS distributions across different pathologists (p = 0.260) and years (p = 0.250) remained consistent. In the matched 43 specimens, TPS concordance between cell block and resection was high (κ = 0.892).
Conclusion
Small biopsies and cell blocks provide reliable PD-L1 results comparable to resection specimens, supporting their use for PD-L1 testing in clinical settings to enhance timely immunotherapy access for NSCLC patients.
FreemanGJLongAJIwaiY, et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-1034. doi:https://doi.org/10.1084/jem.192.7.1027
3.
IshidaYAgataYShibaharaKHonjoT. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887-3895. doi:https://doi.org/10.1002/j.1460-2075.1992.tb05481.x
4.
GaronEBRizviNAHuiR, et al.Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028. doi:https://doi.org/10.1056/NEJMoa1501824
5.
ReckMRodriguez-AbreuDRobinsonAG, et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833. doi:https://doi.org/10.1056/NEJMoa1606774
6.
HerbstRSGiacconeGde MarinisF, et al.Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328-1339. doi:https://doi.org/10.1056/NEJMoa1917346
7.
Mino-KenudsonMSchalperKCooperW, et al.Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee. J Thorac Oncol. Dec 2022;17(12):1335-1354. doi:https://doi.org/10.1016/j.jtho.2022.09.109
8.
Paz-AresLSpiraARabenD, et al.Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020;31(6):798-806. doi:https://doi.org/10.1016/j.annonc.2020.03.287
9.
ReckMRodriguez-AbreuDRobinsonAG, et al.Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537-546. doi:https://doi.org/10.1200/JCO.18.00149
10.
TopalianSLHodiFSBrahmerJR, et al.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454. doi:https://doi.org/10.1056/NEJMoa1200690
11.
RielyGJWoodDEEttingerDS, et al.Non-Small cell lung cancer, version 4.2024. J Natl Compr Canc Netw. 2024;22(4):249-274. doi:https://doi.org/10.6004/jnccn.2204.0023
12.
TsaoMSKerrKMKockxM, et al.PD-L1 Immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13(9):1302-1311. doi:https://doi.org/10.1016/j.jtho.2018.05.013
13.
ButtnerRGosneyJRSkovBG, et al.Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol. 2017;35(34):3867-3876. doi:https://doi.org/10.1200/JCO.2017.74.7642
14.
HirschFRMcElhinnyAStanforthD, et al.PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12(2):208-222. doi:https://doi.org/10.1016/j.jtho.2016.11.2228
15.
TakadaKToyokawaGShojiFOkamotoTMaeharaY. The significance of the PD-L1 expression in non-small-cell lung cancer: trenchant double swords as predictive and prognostic markers. Clin Lung Cancer. 2018;19(2):120-129. doi:https://doi.org/10.1016/j.cllc.2017.10.014
16.
AmbrosiFGiunchiFCapizziE, et al.Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples. Pathol Res Pract. 2022;233(6):153893. doi:https://doi.org/10.1016/j.prp.2022.153893
17.
HeymannJJBulmanWASwinarskiD, et al.PD-L1 expression in non-small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol. 2017;125(12):896-907. doi:https://doi.org/10.1002/cncy.21937
18.
KulacIAydinABulutayPFiratP. Efficiency of cytology samples for PD-L1 evaluation and comparison with tissue samples. Turk Patoloji Derg. 2020;36(3):205-210. Efficiency of Cytology Samples for PD-L1 Evaluation and Comparison with Tissue Samples. doi:https://doi.org/10.5146/tjpath.2020.01494.
19.
LozanoMDAbengozar-MuelaMEchevesteJI, et al.Programmed death-ligand 1 expression on direct pap-stained cytology smears from non-small cell lung cancer: comparison with cell blocks and surgical resection specimens. Cancer Cytopathol. 2019;127(7):470-480. doi:https://doi.org/10.1002/cncy.22155
20.
MansourMSILindquistKESeidalT, et al.PD-L1 Testing in cytological non-small cell lung cancer specimens: a comparison with biopsies and review of the literature. Acta Cytol. 2021;65(6):501-509. doi:https://doi.org/10.1159/000517078
21.
NollBWangWLGongY, et al.Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. Cancer Cytopathol. 2018;126(5):342-352. doi:https://doi.org/10.1002/cncy.21987
22.
SinclairWKobalkaPRenR, et al.Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens. Diagn Cytopathol. 2021;49(2):219-225. doi:https://doi.org/10.1002/dc.24651
23.
RebelattoMCMidhaAMistryA, et al.Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol. 2016;11(1):95. doi:https://doi.org/10.1186/s13000-016-0545-8
24.
PostmusPEKerrKMOudkerkM, et al.Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1-iv21. doi:https://doi.org/10.1093/annonc/mdx222
25.
DangTOOgunniyiABarbeeMSDrilonA. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther. 2016;16(1):13-20. doi:https://doi.org/10.1586/14737140.2016.1123626
26.
RizviNAMazieresJPlanchardD, et al.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257-265. doi:https://doi.org/10.1016/S1470-2045(15)70054-9
27.
ReckMRodriguez-AbreuDRobinsonAG, et al.Five-Year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >/= 50. J Clin Oncol. 2021;39(21):2339-2349. doi:https://doi.org/10.1200/JCO.21.00174
28.
ChampiatSDercleLAmmariS, et al.Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920-1928. doi:https://doi.org/10.1158/1078-0432.CCR-16-1741
29.
DengHZhaoYCaiX, et al.PD-L1 expression and tumor mutation burden as pathological response biomarkers of neoadjuvant immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;170(1):103582. doi:https://doi.org/10.1016/j.critrevonc.2022.103582
30.
LuSSteinJERimmDL, et al.Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5(8):1195-1204. doi:https://doi.org/10.1001/jamaoncol.2019.1549
31.
LuchiniCBibeauFLigtenbergMJL, et al.ESMO Recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232-1243. doi:https://doi.org/10.1093/annonc/mdz116
32.
ShiYLeiYLiuL, et al.Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Cancer Med. 2021;10(7):2216-2231. doi:https://doi.org/10.1002/cam4.3649
33.
VanderwaldeASpetzlerDXiaoNGatalicaZMarshallJ. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018;7(3):746-756. doi:https://doi.org/10.1002/cam4.1372
PinatoDJHowlettSOttavianiD, et al.Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol2019;5(12):1774-1778. doi:https://doi.org/10.1001/jamaoncol.2019.2785
36.
MeloskyBChuQJuergensRA, et al.Breaking the biomarker code: pD-L1 expression and checkpoint inhibition in advanced NSCLC. Cancer Treat Rev. 2018;65:65-77. doi:https://doi.org/10.1016/j.ctrv.2018.02.005
37.
NosakiKSakaHHosomiY, et al.Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135(Suppl. 4):188-195. doi:https://doi.org/10.1016/j.lungcan.2019.07.004
38.
PassigliaFBronteGBazanV, et al.PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget. 2016;7(15):19738-19747. doi:https://doi.org/10.18632/oncotarget.7582
39.
ZhangBLiuYZhouSJiangHZhuKWangR. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: a meta-analysis. Int Immunopharmacol. 2020;80(6):106214. doi:https://doi.org/10.1016/j.intimp.2020.106214
40.
TwomeyJDZhangB. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23(2):39. doi:https://doi.org/10.1208/s12248-021-00574-0
41.
BubendorfLLantuejoulSde LangenAJThunnissenE. Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series “Pathology for the clinician” Edited by Peter Dorfmuller and Alberto Cavazza. Eur Respir Rev. 2017;26(144):170007. https://doi.org/10.1183/16000617.0007-2017
42.
IlieMLong-MiraEBenceC, et al.Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27(1):147-153. doi:https://doi.org/10.1093/annonc/mdv489
43.
VigliarEMalapelleUIaccarinoA, et al.PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory. J Clin Pathol. 2019;72(6):412-417. doi:https://doi.org/10.1136/jclinpath-2019-205732
44.
SmithAWangHZerboA, et al.Programmed death ligand 1 testing of endobronchial ultrasound-guided transbronchial needle aspiration samples acquired for the diagnosis and staging of non-small cell lung cancer. J Bronchol. Interv Pulmonol. 2020;27(1):50-57. doi:https://doi.org/10.1097/LBR.0000000000000623
45.
Russell-GoldmanEKravetsSDahlbergSEShollLMViveroM. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. Cancer Cytopathol. 2018;126(4):253-263. doi:https://doi.org/10.1002/cncy.21973
46.
MunariEZamboniGSigheleG, et al.Expression of programmed cell death ligand 1 in non-small cell lung cancer: comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. Cancer Cytopathol. 2019;127(1):52-61. doi:https://doi.org/10.1002/cncy.22083
47.
JugRGiovacchiniCXLiuB, et al.EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer. J Am Soc Cytopathol. 2020;9(6):485-493. doi:https://doi.org/10.1016/j.jasc.2020.04.003
48.
Ambrosini-SpaltroADubiniAPieriFRavagliaCDelmonteAPolettiV. PD-L1 expression in NSCLC: role of cell blocks and concordance between samples. Diagn Cytopathol. 2021;49(2):303-310. doi:https://doi.org/10.1002/dc.24646
49.
HendrySByrneDJChristieM, et al.Adequate tumour cellularity is essential for accurate PD-L1 immunohistochemistry assessment on cytology cell-block specimens. Cytopathology. 2020;31(2):90-95. doi:https://doi.org/10.1111/cyt.12795
50.
JainDNambirajanABorczukA, et al.Immunocytochemistry for predictive biomarker testing in lung cancer cytology. Cancer Cytopathol. 2019;127(5):325-339. doi:https://doi.org/10.1002/cncy.22137
